drugset / Trial / NCT06861413

A Phase 1 Study to Evaluate the Relative Bioavailability of a VX-828 Tablet Formulation

NCT06861413

Phase 1 Completed 68 enrolled Vertex Pharmaceuticals Incorporated
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the relative bioavailability of a VX-828 tablet formulation compared to a suspension and evaluate its safety and tolerability.

Timeline

Start
2025-04-01
Primary completion
2025-05-05
Completion
2025-05-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator VX-828 Unknown Oral

Indications